Why did Dr. Marty Makary resign as FDA commissioner, and who decided his removal?

Dr. Marty Makary resigned after a rocky 13-month tenure marked by complaints from health industry executives, anti-abortion activists, vaping lobbyists, and other Trump allies; he struggled to manage the FDA’s bureaucracy, lost staff confidence amid mass layoffs and leadership upheavals, and faced controversies where scientific principles appeared overridden by political interests—including those of Health Secretary Robert F. Kennedy Jr. The decision to remove Makary was made by Kennedy, and the White House signed off on it, according to an anonymous administration official.

Who is set to replace Makary as acting FDA commissioner, and what is notable about his background?

Kyle Diamantas, the FDA’s chief for foods, is expected to serve as acting commissioner; he is an attorney with personal ties to Donald Trump Jr., as confirmed by President Trump in a social media post that also included what appeared to be Makary’s resignation text message citing '50 major FDA reforms' and thanking Trump for the opportunity to serve.

Trump’s FDA Chief Resigns After Clashing with Pharma Executives and Lobbyists

May 13, 2026

FDA Commissioner Marty Makary resigned after clashing with pharmaceutical executives and lobbyists over drug approvals and regulatory policies. Acting Commissioner Kyle Diamantas is expected to lead the agency amidst uncertainty regarding vaccine reviews and mifepristone restrictions.

apnews

2026-05-12

Marty Makary Leaves Mixed Legacy as FDA Commissioner

2026-05-13

Makary exit may temporarily lift biotech sentiment but FDA leadership vacuum looms

2026-05-13

Trump’s FDA Chief Resigns After Clashing with Pharma Executives and Lobbyists

Trump’s FDA Chief Resigns After Clashing with Pharma Executives and Lobbyists

FAQ